Timothy P Heffron
Overview
Explore the profile of Timothy P Heffron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tellis J, Wei B, Siu M, An L, Chan G, Chen Y, et al.
ACS Med Chem Lett
. 2024 Sep;
15(9):1606-1614.
PMID: 39291002
Hematopoietic progenitor kinase 1 (HPK1) serves a key immunosuppressive role as a negative regulator of T-cell receptor (TCR) signaling. HPK1 loss-of-function is associated with augmentation of immune function and has...
2.
Meng L, Chan E, Ng C, Aimi J, Tran J, Oh A, et al.
Anal Chem
. 2022 Sep;
94(37):12927-12933.
PMID: 36083155
is one of the most frequently mutated oncogenes, with KRAS G12C recently becoming an actionable target for small molecule intervention. GDC-6036 is an investigational KRAS G12C inhibitor that acts by...
3.
Chan B, Seward E, Lainchbury M, Brewer T, An L, Blench T, et al.
ACS Med Chem Lett
. 2022 Jan;
13(1):84-91.
PMID: 35059127
Hematopoietic progenitor kinase 1 (HPK1) is implicated as a negative regulator of T-cell receptor-induced T-cell activation. Studies using HPK1 kinase-dead knock-in animals have demonstrated the loss of HPK1 kinase activity...
4.
Song K, Edgar K, Hanan E, Hafner M, Oeh J, Merchant M, et al.
Cancer Discov
. 2021 Sep;
12(1):204-219.
PMID: 34544753
is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have...
5.
Liu X, Liang X, LeCouter J, Ubhayakar S, Chen J, Cheng J, et al.
Drug Metab Dispos
. 2020 Mar;
48(5):408-419.
PMID: 32132091
The objectives of the present study were to characterize GNE-947 for its phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitory activities, in vitro anti-cell migration activity in human...
6.
Bronner S, Merrick K, Murray J, Salphati L, Moffat J, Pang J, et al.
Bioorg Med Chem Lett
. 2019 Jul;
29(16):2294-2301.
PMID: 31307887
CDK4 and CDK6 are kinases with similar sequences that regulate cell cycle progression and are validated targets in the treatment of cancer. Glioblastoma is characterized by a high frequency of...
7.
Wu P, Sneeringer C, Pitts K, Day E, Chan B, Wei B, et al.
Structure
. 2018 Dec;
27(1):125-133.e4.
PMID: 30503777
Enhancement of antigen-specific T cell immunity has shown significant therapeutic benefit in infectious diseases and cancer. Hematopoietic progenitor kinase-1 (HPK1) is a negative-feedback regulator of T cell receptor signaling, which...
8.
Heffron T
Neuro Oncol
. 2017 Oct;
20(3):307-312.
PMID: 29016919
Despite biological rationale and significant clinical study, the pursuit of small-molecule kinase inhibitors for the treatment of brain cancers has had very limited success. This Advance-in-Brief discusses the need for...
9.
Levin V, Abrey L, Heffron T, Tonge P, Dar A, Weiss W, et al.
CNS Oncol
. 2017 Jul;
6(3):167-177.
PMID: 28718326
The 2016 second CNS Anticancer Drug Discovery and Development Conference addressed diverse viewpoints about why new drug discovery/development focused on CNS cancers has been sorely lacking. Despite more than 70,000...
10.
Salphati L, Alicke B, Heffron T, Shahidi-Latham S, Nishimura M, Cao T, et al.
Drug Metab Dispos
. 2016 Sep;
44(12):1881-1889.
PMID: 27638506
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Limited treatment options have only marginally impacted patient survival over the past decades. The phophatidylinositol 3-kinase (PI3K) pathway,...